Introduction
Priapism is an emergency pathological condition where an erection lasts for more than 4 hours without any sexual stimulation. 1, 2 The ischemic process in priapism results from blood stasis due to vein occlusion which causes severe hypoxia and acidosis in the corpora cavernosa, leading to fibrosis and damage to the function of the corpora cavernous and permanent erectile dysfunction.
analyzed a sample of corpora cavernosa tissue from a patient with history of priapism and compared it with the normal penis. Result of the study showed that there was an increase in collagen deposition and reduction in smooth-muscle components in the corpora cavernosa with a history of priapism. 4 Various studies have been conducted to overcome fibrosis of the corpora cavernosa, with the aim of ameliorating erectile dysfunction, such as PDE5 inhibitors,pentoxifylline and eventually surgical treatment with a penile implant. Overall, these treatments focused only on restoration of erectile function, rather than prevention of fibrotic tissue formation. 6, 7 In recent years, many studies have shown the potential antifibrotic effect of adipose tissue-derived stem cells (ADSCs) in many animal models. ADSCs are mesenchymal SCs that exhibit tissue plasticity and fusiform morphology in vitro. ADSCs have been used as therapy for injured-organ regeneration in animal models and in a few clinical trials. Effects of ADSCs are attributed to their extensive secretomes, which include interleukins, various growth factors, and other proteins that are suitable inducers of tissue regeneration. [8] [9] [10] [11] Li et al showed that ADSC reduced collagen type I, type III, and α-smooth muscle actin (αSMA) in vitro. 12 Spiekman found that ADSCs suppressed TGFβ 1 expression and reduced dermal scar formation. 13 With recent evidence of antifibrotic effects of ADSCs, this preliminary study aimed to evaluate the potential antifibrotic effect of human ADSCs (hADSCs) in an experimental model of priapism.
Methods

Human ADSC Isolation and Characterization
Human adipose tissue was obtained from adult male/female undergoing surgery who had previously signed an informed consent regarding donation of his/her fat for research. The protocol was approved by the Research and Ethical Committee of Universitas Airlangga Surabaya, which also approved the fat-procurement procedure. Cells were harvested and seeded until passage 3 to achieve greater expansion. 
Wistar Rat Priapism Model
Eighteen male Wistar rats (n=4/group and two rats for negative-control group) weighing 250-300 g were separated into five groups. All operations were performed under sterile conditions. The animals were anesthetized with a one-shot ketamine injection (75 mg/kg intraperitoneally). Priapism was accomplished as per Sanli et al. 14 The tip of a 50 mL syringe was cut to accommodate the device at the base of the flaccid penis, so a vacuum erection device was created. Before application of the vacuum to the penis, a constriction band cut from 16 Fr Foley catheter in 1 mm slices was loaded around the tip of the vacuum erection device. Then, the tip of the syringe was placed on the base of the penis and withdrawn gently to induce erection. After induction of erection, the constriction band was placed on the base of the penis by slipping off the constrictor band from the syringe ( Figure 1 ). Two groups, each consisting of four male Wistar rats with priapism without hADSC therapy injected with 1 mL saline intracorporeally immediately after 12 hours of penile clamping, were euthanized after 2 and 4 weeks of observation (group I), while two other groups, each consisting of four rats with priapism, were given 10 6 cells intracorporeal hADSC injections after 12 hours of penile clamping, and immediately after the clamps were released were euthanized after 2 and 4 weeks of observation (group II). The last group consisted of two rats without any treatment or model (group III). After euthanasia, each rat underwent penectomy for TGFβ 1 and collagen type I analysis. The tissue was processed and 1 g tissue extracted for TGFβ 1 and collagen type I measurement. ELISA measurements were done (FineTest Rat Col1 ELISA kit range 0.156-10 ng/mL and FineTest TGFβ 1 ELISA kit range 31.25-2,000 pg/mL). All animals used in this study were housed in solid plastic cages with four rats in each cage. The rats were allowed to eat standard rodent chow and water ad libitum. This study was conducted in the Biochemical and Bioscience Laboratory, Brawijaya University Malang, and was given ethical clearance by the ethical committee. All study subjects received treatment according to animal welfare guidelines as per Russel and Burch. 15 For statistical analysis, values are expressed as means ± SD (ng/mL). Groups were compared with independent-sample t-tests. Values of p<0.05 were considered statistically significant. Statistical analysis was conducted using SPSS version 21.0.
Results
TGFβ 1 Concentration
TGFβ 1 examination using ELISA showed that there was a concentration difference between group I (control) and group II (hADSC treatment). TGFβ 1 concentration was higher in the control group, than the treatment group in the second and fourth weeks of observation. Independent-sample t-tests were used to compare group I and group II at the time of observation, while group III was excluded from comparison and acted only as as tissue-concentration baseline. There were significant differences in TGFβ 1 concentration between group I and group II in the second (p=0.004) and fourth weeks of observation (p=0.003). Though there was also a tendency toward TGFβ 1 -concentration increase in group II, progression was higher in group I (Table 1 , Figures 2 and 3 ).
Collagen Type I Concentration
Collagen type I examination using ELISA showed that the collagen type I concentrations were higher in group I than group II in the second and fourth weeks of observation. On independent-sample t-tests, there were significant differences in collagen type I concentration between group I and group II in the second (p=0.003) and fourth weeks of observation (p=0.011; Table 2 and Figures 4 and 5) . Based on Table 2 and Figures 4 and 5 ,it can be seen that the largest data variation was at 2 weeks for the control, because it had the highest average compared to 2 weeks' therapy.
Discussion
Fibrosis is the end result of various chronic diseases, such as chronic kidney disease, heart failure, hepatic cirrhosis, and various chronic processes in the urogenital organs. In fibrotic tissue, fibroblasts will differentiate into myofibroblasts and produce large amounts of extracellular matrix, characterized by increased collagen type I and type III concentrations.-Mesenchymal SCs have successfully prevented the growth of fibrotic tissue in experimental and preclinical studies. 16 Mesenchymal SC transplantation is also able to inhibit the formation of fibrotic tissue and to restore the functions of previously disturbed organs, such as the heart, liver, and lungs. 12, 13, 17 This research was conducted in vivo on experimental animals -Wistar rats. The Wistar rat was chosen in this study due to the similarities of its penis structure to humans. 18 An increase in TGFβ 1 concentration was observed over time in the priapism control group. In the hADSC-therapy group, TGFβ 1 concentrations also tended to increase, especially at the second and fourth weeks of therapy. However, the increase in TGFβ 1 concentrations in hADSCs therapy group was lower than the priapism control group. This result is in accordance with research conducted by Spiekman, where in vitro hADSC reduced TGFβ 1 concentrations and extracellular matrix deposition in petri dishes. 13 This research also showed that hADSCs were able to restore fibroblast proliferation to its original level, even after stimulation by TGFβ 1 . RiveraValdes et al in 2017 showed that human ADSC therapy in a renal failure model in Wistar rats significantly decreased renal fibrosis, improved creatinine urea levels, and reduced collagen type I and TGFβ 1 levels in the kidney. 19, 20 This was most likely caused by various secretomes produced by ADSCs, such as VEGF, HGF, GM-CSF, bFGF, BDNF, and IGF1, and various interleukins, such as IL6, IL7, IL8, IL11, and IL10, which contribute to improvement of the tissue microenvironment, but the exact mechanism of how hADSCs inhibit TGFβ 1 is still unclear. 21, 22 This study also found an increase in type I collagen concentration over time in the priapism control group. In the hADSC-therapy group, the concentration of type I collagen also tended to increase at the second and fourth weeks of therapy, but when compared with the control group, the concentration of type I collagen in the human ADSC-therapy group was lower than the control group. This is in accordance with by Li et al, who showed inhibition of collagen I, collagen type III, and αSMA expression in hypertrophic wound tissue in vitro. In addition, ADSC scan also suppress collagen deposition in the matrix of the tissue, thus correcting the fibrosis of the cicatrices ex vivo. The study also showed the antifibrotic effect of ADSC by regulating the p38-MAPK pathway, thereby decreasing type I and type III collagen expression and correcting fibrotic tissue. 13 Another finding of this study is that an increase in TGFβ 1 and type I collagen concentrations over time in the second and fourth weeks of monitoring was observed. This showed that the effect of hADSC administration at the beginning of the treatment did not prevent the progression of the ongoing fibrosis. This finding was not demonstrated by previous studies that examined the antifibrotic effect of hADSCs in other experimental animals, as they only assessed the effect of ADSCs in a single observation. [22] [23] [24] [25] Increased collagen deposition in both the control and the hADSC-therapy group is thought to have been caused by the increase in TGFβ 1 concentrations in the second and fourth weeks of monitoring.
With the presence of TGFβ 1 , molecular signals for fibroblast differentiation and fibroblast collagen production will continue to exist. The main issue of this finding is the progressively increasing concentrations of TGFβ 1 in the HADSC-therapy group in the fourth week of monitoring. Several possibilities may have caused this problem, such as penile tissue damage, including blood vessels that supply the tissue of the penis in the process of priapism modeling, due to mechanical pressure caused by the rubber applied at the base of the penis. With reduced blood flow, the potency of tissue repair by ADSCs to the implanted penis tissue might have been decreased due to reduced oxygen supply. Another thing that will have to be considered is the necessity for periodic ADSC therapy with optimal dosages to maintain the microenvironment, in order to optimize prevention of fibrosis. In addition, a limitation of this study was a lack of assessment of collagen type III and αSMA), which might be useful in further characterizing fibrotic tissue composition and inhibition by hADSCs. TGF and collagen tissue assessment using PCR and Western blot would also be superior to ELISA to detect tissue gene expression. Another limitation in this study was that we did not evaluate histopathological changes in the corpora cavernosa or functional changes that might have contributed greatly to the study results.
Although an ability to repair damaged tissue without the formation of scar tissue is thought to be ideal, in most chronic inflammatory diseases the regeneration process cannot be completed by merely parenchymal cell regeneration, even in tissue with fast regeneration capability. The damaged tissue must be repaired by replacing parenchymal cells with scar tissue, eventually causing significant fibrosis. As such, ADSCs are an interesting alternative to prevent the process Figure 4 Collagen type I standard-error chart: second and fourth weeks of observation. of fibrosis in various tissue injuries in general, and offer possibilities for the prevention of erectile dysfunction due to cavernous corpora fibrosis in priapism. However, further research is needed.
Conclusion
Intracorporeal hADSC administration decreased TGFβ 1 and collagen type I concentration in a low-flow priapism model. This is possibly an interesting novel treatment for fibrotic tissue prevention in low-flow priapism. However, further research should be done to investigate the exact mechanism of fibrosis prevention in cavernosa tissue by hADSCs and suitable routes and timing of administration of hADSCs before we could use them safely in human subjects.
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